Archives
AG-120 (Ivosidenib): A Metabolic Assay Guide
2026-08-12
AG-120 (Ivosidenib) is a selective mutant IDH1 inhibitor that connects 2-hydroxyglutarate reduction with leukemia-cell differentiation. This guide translates recent CD44-dependent metabolic findings into a practical framework for designing and interpreting mechanistic assays.
Hepatic sEH–Nrf2 Axis in Osteoporosis
2026-08-11
The reference study identifies a liver–bone mechanism in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppresses Nrf2–ARE signaling, and promotes osteoclast differentiation. By combining clinical samples, an ovariectomy-induced mouse model, liver-specific knockdown, pharmacological inhibition, transcriptomics, and cell-based validation, the work connects hepatic lipid metabolism with redox imbalance in osteoporosis.
Biotin-XX Tyramide Reagent for TSA
2026-08-11
Biotin-XX Tyramide Reagent, also called biotin-LC-LC-tyramide, is a membrane-impermeant HRP substrate for localized biotin deposition. Its long polar linker supports cell surface protein labeling, while the tyramide reaction increases detection sensitivity in IHC, ISH, and proximity-labeling workflows.
Nitroaromatic Nannocystin Targets AKT1 in CRC
2026-08-10
This 2024 Acta Pharmacologica Sinica study identifies a nitroaromatic nannocystin, compound 4, as a potent colorectal cancer inhibitor with activity in cell models, patient-derived organoids, and xenografts. Its combined synthesis, phenotypic profiling, RNA sequencing, molecular docking, and cellular thermal shift analysis supports AKT1 as a mechanistic target and provides a framework for evaluating macrocyclic targeted agents.
Sulfachloropyridazine: DHPS Research Guide
2026-08-09
Sulfachloropyridazine is a sulfonamide antibacterial agent and competitive inhibitor of dihydropteroate synthase (DHPS). Its research value spans recombinant enzyme inhibition, antimicrobial susceptibility testing, microbiome analysis, and carefully controlled in vivo infection models.
PP 1: Mapping Src Signaling Beyond Potency
2026-08-08
PP 1, a Src family tyrosine kinase inhibitor, can do more than suppress phosphorylation: it can help researchers distinguish kinase-node effects from network-level consequences. This article connects Lck, Fyn, Lyn, RET, and CSK biology to more rigorous cancer and immune assay design.
Pregnenolone Carbonitrile: Reliable Cell Assays
2026-08-07
Learn how Pregnenolone Carbonitrile (SKU C3884) can improve experimental control in PXR, cell viability, and hepatic detoxification workflows. This scenario-based guide covers compatibility, protocol design, data interpretation, and practical supplier selection.
Amikacin (BAY416651): Next-Gen Insights for Resistance Mecha
2026-08-07
Explore the latest scientific advances in Amikacin (BAY416651) applications, focusing on resistance mechanisms in Enterobacter cloacae and Klebsiella pneumoniae. This article uncovers how cutting-edge genomic surveillance informs practical antibiotic resistance research.
Transmission Dynamics of Carbapenemase Genes in CREC in Chin
2026-08-06
This study systematically characterizes the prevalence and transferability of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals in Guangdong, China. The findings reveal high rates of multidrug resistance and efficient gene transfer, particularly involving the blaNDM−1 gene, with important implications for the management of Gram-negative bacterial infections.
Demethyleneberberine: Advanced Protocols for Oncology and In
2026-08-06
Demethyleneberberine (DMB) streamlines translational research on inflammation and cancer by targeting c-Myc/HIF-1α and NF-κB/MAPK pathways. This guide delivers actionable workflows, troubleshooting tips, and comparative insights for maximizing the value of DMB in complex in vitro and in vivo models.
Novobiocin Sodium: Optimizing DNA Damage and Antiparasitic A
2026-08-05
Novobiocin Sodium, a potent aminocoumarin antibiotic, provides researchers with a robust tool for investigating DNA replication, metabolic enzyme pathways, and antiparasitic mechanisms. This guide translates recent high-impact findings into actionable workflows, advanced troubleshooting, and comparative insights—empowering biomedical labs to maximize data quality and assay specificity.
Pseudo-UTP: Empowering Next-Gen mRNA Vaccine and RNA Therapy
2026-08-05
Discover how pseudo-modified uridine triphosphate (Pseudo-UTP) revolutionizes mRNA synthesis for vaccines and gene therapy. This in-depth analysis explores unique stability, translational efficiency, and practical protocol strategies for advanced RNA research.
Iron-Dependent KDM4D Regulates MSC Quiescence via PI3K-Akt-F
2026-08-04
This study identifies KDM4D as a key iron-dependent histone demethylase controlling the activation of quiescent mesenchymal stem cells (MSCs) through the PI3K-Akt-Foxo1 pathway. The findings provide a mechanistic link between iron deficiency, epigenetic regulation, and impaired bone remodeling, highlighting new targets for osteoporosis and metabolic research.
MK-4827 (Niraparib): Advanced PARP1/2 Inhibition for Spliceo
2026-08-04
Explore how MK-4827 (Niraparib), a potent PARP1/2 inhibitor, is opening new frontiers in cancer research by targeting spliceosome regulation and DNA repair beyond classical BRCA paradigms. Discover actionable insights for assay design and translational applications.
Practical Guide to YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2
2026-08-03
YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a research-grade small molecule used for inhibition of hypoxia-inducible factor 1 transcriptional activity and sGC activation, essential in workflows investigating tumor hypoxia, angiogenesis, and related processes. This compound is optimal for in vitro and in vivo research on cancer biology but is not intended for diagnostic or therapeutic applications. Careful attention to solubility, storage, and workflow setup is required for reproducible results.
608 records 12/41 page Previous Next First page 上5页 1112131415 下5页 Last page